Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C V Fletcher

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The Journal of Infectious Diseases|July 7, 2000
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adultsJ M Jacobson, I Lowy, C V Fletcher, et al.
The Journal of Antimicrobial Chemotherapy|November 26, 2020
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB preventionA T Podany, J Leon-Cruz, J Hakim, et al.
Pediatrics|April 2, 1999
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 TeamM W Kline, S Blanchard, C V Fletcher, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1996
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSH H Balfour, C V Fletcher, A Erice, et al.
The Journal of Infectious Diseases|October 7, 2000
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359R M Gulick, X J Hu, S A Fiscus, et al.
The Journal of Infectious Diseases|November 9, 2000
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study TeamW T Shearer, R J Israel, S Starr, et al.
The Journal of Infectious Diseases|February 1, 1997
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study GroupJ S Lambert, L M Mofenson, C V Fletcher, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
The Journal of Infectious Diseases|February 11, 2000
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273)E R Stiehm, C V Fletcher, L M Mofenson, et al.
The New England Journal of Medicine|December 22, 1999
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 TeamS E Starr, C V Fletcher, S A Spector, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Journal of Infectious Diseases|July 7, 2000
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adultsJ M Jacobson, I Lowy, C V Fletcher, et al.
The Journal of Antimicrobial Chemotherapy|November 26, 2020
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB preventionA T Podany, J Leon-Cruz, J Hakim, et al.
Pediatrics|April 2, 1999
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 TeamM W Kline, S Blanchard, C V Fletcher, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1996
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSH H Balfour, C V Fletcher, A Erice, et al.
The Journal of Infectious Diseases|October 7, 2000
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359R M Gulick, X J Hu, S A Fiscus, et al.
The Journal of Infectious Diseases|November 9, 2000
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study TeamW T Shearer, R J Israel, S Starr, et al.
The Journal of Infectious Diseases|February 1, 1997
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study GroupJ S Lambert, L M Mofenson, C V Fletcher, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
The Journal of Infectious Diseases|February 11, 2000
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273)E R Stiehm, C V Fletcher, L M Mofenson, et al.
The New England Journal of Medicine|December 22, 1999
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 TeamS E Starr, C V Fletcher, S A Spector, et al.
Pageof 7